Fierce Pharma

Rocket plots measured trajectory for new gene therapy Kresladi after clearance to launch from FDA

With an end-of-week green light from the FDA, Rocket Pharmaceuticals has officially broken into commercial orbit.  | Rocket ...
BioPharma Dive

Rocket gene therapy cleared by FDA for rare immune disorder

Though the therapy, Kresladi, isn’t seen as a big seller, its clearance is a step forward for a company that’s lost most of ...

UCLA-led gene therapy clinical trial leads to FDA approval for rare immune disorder

A groundbreaking gene therapy tested through a UCLA-led clinical trial has received approval from the U.S. Food and Drug ...

Rocket’s gene therapy Kresladi wins FDA approval in rare immune disease

Upon approval, Rocket has been awarded a priority review voucher, which currently fetch around $200m on the secondary market.

Rocket Pharmaceuticals Wins FDA Accelerated Approval for KRESLADI Gene Therapy in Severe LAD-I Kids

Rocket Pharmaceuticals (NASDAQ:RCKT) said the U.S. Food and Drug Administration has granted accelerated approval to KRESLADI ...
Zacks Investment Research on MSN

RCKT stock down despite FDA nod to gene therapy in rare disease

Rocket Pharmaceuticals RCKT announced that the FDA has granted accelerated approval to its gene therapy Kresladi ...
pharmaphorum

Touchdown for Rocket as its first gene therapy gets US okay

At its second attempt, Rocket Pharma has won FDA approval for its gene therapy for severe leukocyte adhesion deficiency type ...

Rocket Pharmaceuticals (RCKT) Is Down 8.9% After FDA Accelerated Approval Of KRESLADI Gene Therapy

Rocket Pharmaceuticals recently announced that the U.S. FDA has granted accelerated approval for KRESLADI (marnetegragene autotemcel), an autologous hematopoietic stem cell-based gene therapy for ...
Stocktwits on MSN

RCKT stock jumps over 10% premarket: FDA approves its first gene therapy for rare childhood immune disease

The FDA approved gene therapy Kresladi, Rocket's first commercial product. ・The approval targets children with severe LAD-I ...
STAT

FDA approves Rocket gene therapy for rare immune disorder

The Food and Drug Administration approved on Thursday a gene therapy for severe leukocyte adhesion deficiency type 1 (LAD-1), ...